Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
United States
University of California, San Diego, La Jolla, California University of California, Los Angeles, Los Angeles, California SCRI - Denver, Denver, Colorado University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida START Midwest, Grand Rapids, Michigan The Christ Hospital, Cincinnati, Ohio NEXT Oncology - Austin, Austin, Texas MD Anderson Cancer Center, Houston, Texas NEXT Oncology - Dallas, Irving, Texas NEXT Oncology - San Antonio, San Antonio, Texas University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah NEXT Virginia, Fairfax, Virginia